Antiphospholipid syndrome – the description of two cases

Česká verzia

Authors: L. Podrazilová ¹; V. Peterová ²; M. Olejárová ¹; Z. Seidl ^2,3; C. Dostál ¹
Authors place of work: Revmatologický ústav, 1. lékařská fakulta UK, Praha, ředitel prof. MUDr. Karel Pavelka, DrSc. ¹; MR oddělení Radiodiagnostické kliniky 1. lékařské fakulty UK a VFN, Praha, přednosta doc. MUDr. Jan Daneš, CSc. ²; Neurologická klinika 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. Soňa Nevšímalová, DrSc. ³
Published in the journal: Vnitř Lék 2006; 52(1): 89-94
Category: Case Report

Summary

Antiphospholipid syndrome (APS) often occurs in young people, it is defined by the presence of venous or arterial thromboses, repeated miscarriages, thrombocytopenias and increased levels of antiphospholipid antibodies. Clinical symptoms are different, there is often experienced the phlebothrombosis of lower limbs, miscarriages or neurological symptoms characterized by transient ischemic attacks (TIA). If APS is associated with other system disease, most often with systemic lupus erythematosus (SLE), it is called secondary APS. We present two cases of secondary APS in the work. In first case we describe synchronous occurrence of SLE with secondary APS, which was clinically manifested by phlebothrombosis of veins of crus. At another elder patient there was stated the diagnosis of non- differentiated disease of bonding agent with secondary APS with cardial, pneumonic and neurological clinical symptoms.

Key words:
primary and secondary antiphospholipid syndromes – antiphospholipid antibodies – cerebral MR

Zdroje

1. Khamasta MA, Hughes GR. The antifosfolipid syndrome. Rheumatology in Europe 1994; 23: 23-25.

2. Asherson RA, Khamashta MA, Ordi-Ros J et al. The primary antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366-374.

3. Vencovský J. Antifosfolipidové protilátky, Antifosfolipidový syndrom. In: Autoimunitní systémová onemocnění. Praha: Triton 1998; 27, 107-110.

4. Scott TF, Hess D, Brillmanm J. Antiphospholipid antibody syndrome mimicking multiple sclerosis clinically and by magnetic resonance imaging. Arch Intern Med 1994; 154: 917-920.

5. Dostál C. Autoprotilátky u systémového lupus erytematodes. In: Dostál C., Vencovský J (eds). Systémový lupus erythematodes. Praha: Medprint 1997; 38-56.

6. Dostál C, Vencovský J et al. Antifosfolipidové protilátky, Antifosfolipidový syndrom. In: Dostál C., Vencovský J (eds). Systémový lupus erytematodes. Praha: Medprint 1997; 57-64, 136-147.

7. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome. Arthritis Rheumatism 2002; 46: 1019-1027.

8. Wasserman A, Neisser A, Bruck C. Eine serodiagnostiche Reaktion bei Syphylis. Deutch Med Wochenschr 1906; 32: 475-489.

9. Caterall RD. Biological false positive reactions and systemic disease. In: Walker G (ed). Ninth Symposium in Advanced Medicine. London: Pitman Medical: 1973; 97-111.

10. Harris EN, Gharavi AE, Boey ML et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 1211-1214.

11. Loizou S, Mc Crea JD, Rudge AC et al. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standartization and quantitation of results. Clin Exp Immunol 1985; 62: 3, 738-745.

12. Feinstein DI, Rapaport SI. Acquired inhibitors of Blood Coagulation. Prog Hemos Thromb 1972; 1: 75-95.

13. Fojtík Z, Beránek M, Klabusay M et al. Výskyt vybraných antifosfolipidových protilátek u skupiny nemocných se systémovým lupus erythematodes. Vnitř Lék 2004; 50: 267-273.

14. Galli M, Comfurius P, Maasem C et al. Anticardiolipin antibodies (ACA) are directed not to cardiolipin but to a plasma cofactor. Lancet 1990; 335: 1544-1547.

15. Mc Neil HP, Simpson RJ, Chesterman CN et al. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: beta2-glykoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.

16. Dostál C. Antifosfolipidový syndrom. In: Pavelka K, Rovenský J. Klinická revmatologie. Praha: Galén 2003; 265-272.

17. Sipek-Dolnicar A, Hojnik M, Bozic B et al. Clinical presentations and vascular histopatology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies. Clin Exp Rheumatol 2002; 20: 335-342.

18. Marai I, Levi Y, Godard G et al. Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population. Harefuah 2001; 140: 495-500.

19. Molad Y, Sidi Y, Gornish M et al. Lupus anticoagulant: correlation with magnetic resonance imagingof brain lesions. J Rheumatol 1992; 19: 556-561.

20. Appenzeller S, Zeller CB, Annichino-Bizzachi JM et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clin Neurol Neurosurg. 2005; 107: 371-378.

21. Kelly BJ, Cronin M, Curran JJ. Anticardiolipin syndrome resembling multiple sclerosis. Arthritis Rheum 1989; 32: S71.

22. Isaac C, Li DK, Genton M et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988; 38: 1511-1515.

23. Ferreira S, Cruz DPD, Hughes GRV. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology 2005; 44: 434-442.

24. Paran D, Chapman J, Korczyn AD et al. Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis. Ann Rheum Dis 2005; 17, abstrakt.

25. Totolian NA. Magnetic- resonance tomography in differential diagnosis of brain lesions in demyelinating and systemic autoimmune diseases. Zh Nevrol Psikhiatr Im S S Korsakova 2005; 105: 42-46.

26. Ingram SB, Goodnight SH, Bennett RM. An unusual syndrome of a devastating noninflammatory vasculopathy associated with anticardiolipin antibodies. Ann Rheum Dis 1988; 47: 681-683.

27. Asherson RA, Derksen RHWM, Harris EN et al. Chorea in systemic lupus erythematosus and „lupus-like“ disease: association with antiphospholipid antibodies. Semin Arthritis Rheum 1987; 16: 253-259.

28. Cauli A, Montaldo C, Peltz MT et al. Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity. Clin Exp Rheumatol 1994; 12: 389-394.

29. Sibbitt WL jr, Sibbitt RR, Griffey RH et al. Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 1014-1022.

30. Peterová V, Dostál C, Linková L et al. The distribution of MR lesions in neuropsychiatric lupus erythematosus and multiple sclerosis patients. J Neuroradiol 2002, Suppl: S40.

31. Linková L, Peterová V, Olejárová M et al. Neuropsychiatrické postižení u pacientů se systémovým lupus erythematodes. Čes Revm 2003; 2, 78-82.

32. Jensen MC, Brant-Zawadski MN, Jacobs BC. Ischemia. In: Magnetic Resonance Imaging. Ed. Mosby 1999, USA, 1255-1274.

33. Harris EN, Gharavi AE, Asherson RA. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 1984; 2: 47-51.

34. Toubi E, Khamashta MA, Panarra A et al. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Amer J Med 1995; 99: 397-401.

35. Levine SR, Deegan MJ, Futrell A et al. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40: 1181-1189.